# A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

> **NCT04493216** · PHASE2 · TERMINATED · sponsor: **ViiV Healthcare** · enrollment: 161 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** GSK3640254
- **DRUG:** ABC/3TC
- **DRUG:** FTC/TAF
- **DRUG:** Dolutegravir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04493216
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-18
- **Primary completion:** 2022-09-05
- **Final completion:** 2023-05-29
- **Target enrollment:** 161 (ACTUAL)
- **Why stopped:** Company decision to stop compound development. The decision is not based on any safety or efficacy concerns. It reflects the company strategy for portfolio progression.
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04493216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04493216, "A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04493216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*